NasdaqGS - Delayed Quote • USD
Regeneron Pharmaceuticals, Inc. (REGN)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:36 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 20 | 26 | 25 |
| Avg. Estimate | 10.1 | 10.91 | 45.15 | 47.65 |
| Low Estimate | 8.56 | 9.27 | 36.48 | 41.73 |
| High Estimate | 11.62 | 12.6 | 52.6 | 56.4 |
| Year Ago EPS | 10.09 | 10.24 | 43.79 | 45.15 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 18 | 26 | 25 |
| Avg. Estimate | 3.22B | 3.4B | 13.95B | 14.97B |
| Low Estimate | 3.07B | 3.15B | 13.04B | 13.69B |
| High Estimate | 3.51B | 3.65B | 14.75B | 17.18B |
| Year Ago Sales | 3B | -- | 13.12B | 13.95B |
| Sales Growth (year/est) | 7.30% | -- | 6.30% | 7.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 9.56 | 9.84 | 10.72 | 10.73 |
| EPS Actual | 10.09 | 10.24 | 11.59 | 11.86 |
| Difference | 0.53 | 0.4 | 0.87 | 1.13 |
| Surprise % | 5.50% | 4.10% | 8.10% | 10.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 10.1 | 10.91 | 45.15 | 47.65 |
| 7 Days Ago | 10.12 | 11.01 | 45.22 | 47.53 |
| 30 Days Ago | 9.96 | 10.95 | 44.78 | 47.27 |
| 60 Days Ago | 10.02 | 11.06 | 44.85 | 47.27 |
| 90 Days Ago | 10.4 | 11.22 | 44.73 | 48.01 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 1 | 2 | 3 |
| Up Last 30 Days | 7 | 6 | 9 | 8 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 2 | -- |
Growth Estimates
| CURRENCY IN USD | REGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.10% | -- | -- | 6.50% |
| Next Qtr. | 6.50% | -- | -- | 12.00% |
| Current Year | 3.10% | -- | -- | 5.30% |
| Next Year | 5.50% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 7.77% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 17.45% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | TD Cowen: Buy to Buy | 4/24/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 4/17/2024 |
| Maintains | UBS: Buy to Buy | 4/17/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 4/15/2024 |
| Maintains | B of A Securities: Underperform to Underperform | 4/12/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 4/9/2024 |
Related Tickers
VRTX Vertex Pharmaceuticals Incorporated
397.48
-0.06%
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
CRSP CRISPR Therapeutics AG
53.91
+0.34%
MRNA Moderna, Inc.
107.97
+1.69%
BNTX BioNTech SE
87.21
+0.58%
NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
INCY Incyte Corporation
51.68
+0.98%
EXEL Exelixis, Inc.
23.70
+0.72%